Hongqian Q. Guo

No. 321 Zhongshan Road
Nanjing, 210008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 380 publications

ASO Visual Abstract: A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.

ASO Visual Abstract: A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.

Journal: Annals of surgical oncology

Published: August 21, 2026

The role of NLRP3 inflammasome in the development of postoperative ileus and its molecular mechanism in male mice.

The role of NLRP3 inflammasome in the development of postoperative ileus and its molecular mechanism in male mice.

Journal: Physiological reports

Published: April 22, 2026

Hierarchical Zeolitic Imidazolate Framework-8@Au Cluster Nanocarriers for In Situ Chimeric Antigen Receptor Macrophage Programming and Immunotherapy in Prostate Cancer.

Hierarchical Zeolitic Imidazolate Framework-8@Au Cluster Nanocarriers for In Situ Chimeric Antigen Receptor Macrophage Programming and Immunotherapy in Prostate Cancer.

Journal: ACS nano

Published: April 08, 2026

A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.

A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.

Journal: Annals of surgical oncology

Published: April 02, 2026

Autologous Vas Deferens Sling for Early Urinary Continence During Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Randomized Controlled Clinical Trial.

Autologous Vas Deferens Sling for Early Urinary Continence During Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Randomized Controlled Clinical Trial.

Journal: Healthcare (Basel, Switzerland)

Published: March 29, 2026

Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.

Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.

Journal: The Journal of urology

Published: February 17, 2026

Research progress of Type II immune responses in cancer therapy

Research progress of Type II immune responses in cancer therapy

Journal: Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Published: February 01, 2026

AGIBOT AM1000 versus da Vinci Xi systems for robot-assisted partial nephrectomy: a retrospective propensity score-matched comparative study.

AGIBOT AM1000 versus da Vinci Xi systems for robot-assisted partial nephrectomy: a retrospective propensity score-matched comparative study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 15, 2026

Single-cell and spatial multi-omics reveal mechanistic insights of FOLH1+ endothelial cells in clear cell renal cell carcinoma.

Single-cell and spatial multi-omics reveal mechanistic insights of FOLH1+ endothelial cells in clear cell renal cell carcinoma.

Journal: Journal of translational medicine

Published: January 06, 2026

Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor.

Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor.

Journal: International journal of biological sciences

Published: December 22, 2025

Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial.

Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial.

Journal: World journal of urology

Published: December 21, 2025

Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening.

Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening.

Journal: Annals of medicine

Published: December 17, 2025

Showing 1-12 of 380

Last Updated: 09/26/2026